YPO to Host World's Top Business Leaders and Innovators at 2018 YPO EDGE in Singapore
DALLAS, Feb. 06, 2018 (GLOBE NEWSWIRE) -- For two days this March, YPO, the global leadership organization for chief executives, will host 2,000 business leaders and innovators from more than 130 countries at the YPO EDGE in Singapore.
Each year, YPO EDGE, the largest gathering of CEOs from around the world, brings together thought leaders, creators and visionaries who are providing new perspectives insights, ideas, technologies and innovations.
The guiding theme of the 2018 EDGE in Singapore is Defy Convention, and the agenda is designed to spark idea exchange and redefine the rules in the entrepreneurial spirit of innovation. The EDGE will explore advances in technology, medicine, health, transportation, machine learning, cybersecurity and more, featuring speakers and resources in business, entertainment, technology, health, philanthropy, science and more.
"Singapore is an ideal host city for the YPO EDGE, as the global gateway to the worlds of business, technology and culture," said Scott Mordell, CEO of YPO. "YPO is thrilled to host its landmark annual event in Singapore, creating opportunities for business leaders to become better leaders and make a significant impact."
More than 40 internationally renowned speakers will be sharing their inspirational stories and transformational innovations including:
- Lee Hsien Loong, Prime Minister of Singapore
- HM Queen Rania Al Abdullah, Queen Consort Hashemite Kingdom of Jordan
- Billie Jean King, American former World No. 1 professional tennis player
- Orit Gadiesh, Chairman, Bain and Company
- Yossi Ghinsberg, Adventurer, Author, Entrepreneur and Humanitarian
- Amin Toufani, Faculty at Singularity University and CEO of T Labs
Speakers at previous YPO EDGE events include Canadian Prime Minister Justin Trudeau; Sir Richard Branson, founder and chairman of the Virgin Group; Muhtar Kent, chairman and CEO of the Coca-Cola Company; Aung San Suu Kyi, Nobel Peace Prize laureate and general secretary of the National League for Democracy; and Archbishop Desmond Mpilo Tutu, Nobel Peace Prize laureate.
"At the 2018 YPO EDGE in Singapore, YPO business leaders will defy convention and leave with new perspectives, ideas and insights that will empower them to positively impact their businesses, their communities and their lives," said YPO EDGE Chair N.K, Tong.
The premier leadership organization of chief executives in the world.
YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world's most influential and innovative business leaders to inspire business, personal, family and community impact.
Today, YPO empowers more than 25,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 16 million people and generate USD6 trillion in annual revenues.
Leadership. Learning. Lifelong. For more information, visit ypo.org.
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: YPO via Globenewswire
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från GlobeNewswire
Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00 | Pressmeddelande
Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu
Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00 | Pressmeddelande
Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski
Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45 | Pressmeddelande
Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im
Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45 | Pressmeddelande
Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech
Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00 | Pressmeddelande
STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum